Trial
NCT05961007
Evaluation of IBI302 Injection in nAMD or DME
Phase ISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Collaborators
—
Condition
Neovascular Age-related Macular Degeneration
Intervention
Intravitreal injection of IBI302(dose 1)
Why stopped
Company strategy adjustment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-27